NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News $24.75 +1.27 (+5.41%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$23.56▼$24.8650-Day Range$23.48▼$40.4452-Week Range$22.80▼$76.36Volume304,785 shsAverage Volume249,034 shsMarket Capitalization$521.24 millionP/E RatioN/ADividend YieldN/APrice Target$56.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside129.3% Upside$56.75 Price TargetShort InterestHealthy3.45% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.89Based on 5 Articles This WeekInsider TradingSelling Shares$2.34 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.34) to ($5.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.73 out of 5 starsMedical Sector129th out of 1,980 stocksPharmaceutical Preparations Industry49th out of 978 stocks 3.3 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.75, Enanta Pharmaceuticals has a forecasted upside of 129.3% from its current price of $24.75.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.45% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 6.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 3.3 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enanta Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,343,321.00 in company stock.Percentage Held by Insiders12.70% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.68% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($6.34) to ($5.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.Read More Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesJune 1, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Down 6.4% in MayMay 31, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Participate at Jefferies Global Healthcare ConferenceJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 13, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Enanta Pharmaceuticals, Inc. Lifted by HC Wainwright (NASDAQ:ENTA)May 12, 2023 | msn.comOppenheimer Reiterates Enanta Pharmaceuticals (ENTA) Perform RecommendationMay 11, 2023 | msn.comEnanta Pharma GAAP EPS of -$1.79 beats by $0.45, revenue of $17.8M beats by $4.91MMay 11, 2023 | seekingalpha.comEnanta Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 11, 2023 | msn.comJMP Securities Maintains Enanta Pharmaceuticals (ENTA) Outperform RecommendationJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 11, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of "Moderate Buy" from BrokeragesMay 10, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPSMay 9, 2023 | markets.businessinsider.comWhy Enanta Shares Are Plunging TodayMay 9, 2023 | marketwatch.comEnanta Pharmaceuticals Shares Slide After Covid-19 Study Update >ENTAMay 9, 2023 | msn.comHC Wainwright & Co. Maintains Enanta Pharmaceuticals (ENTA) Buy RecommendationMay 9, 2023 | msn.comEnanta Pharma Tanks as Losses Widen in Q2May 9, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Two Investor Conferences in MayMay 9, 2023 | americanbankingnews.comRoyal Bank of Canada Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $33.00May 9, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $65.00 Price Target at JMP SecuritiesMay 9, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $48.00May 9, 2023 | markets.businessinsider.comEnanta Pharmaceuticals (ENTA) Receives a Buy from JMP SecuritiesMay 9, 2023 | seekingalpha.comANTRA, ENTA and YMAB are among after hour moversMay 8, 2023 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ETMay 8, 2023 | msn.comEnanta falls 21% as fiscal 2023 Q2 revenue missesMay 5, 2023 | msn.comEnanta Pharma Earnings PreviewMay 2, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023April 27, 2023 | finance.yahoo.comENTA: Lowering target price to $36.00April 25, 2023 | marketwatch.comEnanta Sells Part of Mavyret/Maviret Royalty for $200 Million >ENTASee More Headlines ENTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Company Calendar Last Earnings5/08/2023Today6/01/2023Next Earnings (Estimated)8/14/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees155Year FoundedN/APrice Target and Rating Average Stock Price Forecast$56.75 High Stock Price Forecast$87.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+129.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,750,000.00 Net Margins-153.61% Pretax Margin-154.08% Return on Equity-40.56% Return on Assets-34.77% Debt Debt-to-Equity RatioN/A Current Ratio8.43 Quick Ratio8.43 Sales & Book Value Annual Sales$86.16 million Price / Sales6.05 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book1.94Miscellaneous Outstanding Shares21,060,000Free Float18,381,000Market Cap$521.24 million OptionableOptionable Beta0.38 Key ExecutivesJay R. LulyPresident, Chief Executive Officer & DirectorPaul J. MellettCFO & Senior VP-Finance & AdministrationYat Sun OrCSO, Senior Vice President-Research & DevelopmentScott T. RottinghausChief Medical Officer & Senior Vice PresidentNathaniel S. GardinerSecretary, Senior Vice President & General CounselKey CompetitorsOrganogenesisNASDAQ:ORGOOcular TherapeutixNASDAQ:OCULAnaptysBioNASDAQ:ANABEvolusNASDAQ:EOLSBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 1,471 shares on 5/22/2023Ownership: 0.555%Putnam Investments LLCSold 1,299 shares on 5/22/2023Ownership: 0.146%JPMorgan Chase & Co.Sold 14,360 shares on 5/18/2023Ownership: 0.794%New York State Common Retirement FundSold 4,800 shares on 5/18/2023Ownership: 0.047%Thrivent Financial for LutheransBought 26,057 shares on 5/17/2023Ownership: 0.219%View All Insider TransactionsView All Institutional Transactions ENTA Stock - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTA shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2023? 8 brokerages have issued 1-year price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $33.00 to $87.00. On average, they predict the company's share price to reach $56.75 in the next year. This suggests a possible upside of 129.3% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2023? Enanta Pharmaceuticals' stock was trading at $46.52 on January 1st, 2023. Since then, ENTA stock has decreased by 46.8% and is now trading at $24.75. View the best growth stocks for 2023 here. Are investors shorting Enanta Pharmaceuticals? Enanta Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 667,800 shares, a decline of 6.4% from the April 30th total of 713,500 shares. Based on an average trading volume of 198,800 shares, the short-interest ratio is currently 3.4 days. Approximately 3.5% of the shares of the stock are sold short. View Enanta Pharmaceuticals' Short Interest. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, May, 8th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.91) by $0.12. The biotechnology company had revenue of $17.80 million for the quarter, compared to analyst estimates of $19.06 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 40.56% and a negative net margin of 153.61%. The company's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.63) earnings per share. What ETFs hold Enanta Pharmaceuticals' stock? ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC). What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.08%), Armistice Capital LLC (9.56%), State Street Corp (5.70%), Braidwell LP (4.93%), Krensavage Asset Management LLC (2.87%) and Dimensional Fund Advisors LP (2.58%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $24.75. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $521.24 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.98) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? The company employs 155 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.